Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-10-09
2007-10-09
Ketter, James (Department: 1636)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S235100
Reexamination Certificate
active
10846181
ABSTRACT:
This invention provides a method for determining susceptibility for an anti-viral drug comprising: (a) introducing a resistance test vector Comprising a patient-derived segment and an indicator gene into a host cell; (b) culturing the host cell from (a); (c) measuring expression of the indicator gene in a target host cell; and (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-viral drug, wherein a test concentration of the anti-viral drug is present at steps (a)-(c); at steps (b)-(c); or at step (c). This invention also provides a method for determining anti-viral drug resistance in a patient comprising: (a) determining anti-viral drug susceptibility in the patient at a first time using the susceptibility test described above, wherein the patient-derived segment is obtained from the patient at about said time; (b) determining anti-viral drug susceptibility of the same patient at a later time; and (c) comparing the anti-viral drug susceptibilities determined in step (a) and (b), wherein a decrease in anti-viral drug susceptibility at the later time compared to the first time indicates development or progression of anti-viral drug resistance in the patient.
REFERENCES:
patent: 4952496 (1990-08-01), Studier et al.
patent: 5126251 (1992-06-01), Moss et al.
patent: 5135855 (1992-08-01), Moss et al.
patent: 5354674 (1994-10-01), Hodgson
patent: 5439809 (1995-08-01), Haynes et al.
patent: 5462873 (1995-10-01), Garfinkel et al.
patent: 5837464 (1998-11-01), Capon et al.
patent: 5866348 (1999-02-01), Scheirer
patent: 5874565 (1999-02-01), Rice et al.
patent: 5985926 (1999-11-01), Leung et al.
patent: 6033902 (2000-03-01), Haseltine et al.
patent: 6127116 (2000-10-01), Rice et al.
patent: 6242187 (2001-06-01), Capon et al.
patent: 2002/0034732 (2002-03-01), Capon et al.
patent: 0 291 893 (1987-05-01), None
patent: 0 291 893 (1988-11-01), None
patent: 0 361 749 (1990-04-01), None
patent: 0 372 904 (1990-06-01), None
patent: 0 414 475 (1991-02-01), None
patent: 98940779.6 (2004-08-01), None
patent: P9900388 (2005-02-01), None
patent: WO91/19798 (1991-12-01), None
patent: WO92/07943 (1992-05-01), None
patent: WO94/08002 (1994-04-01), None
patent: WO94/19478 (1994-09-01), None
patent: WO94/29438 (1994-12-01), None
patent: WO95/05453 (1995-02-01), None
patent: WO95/22622 (1995-08-01), None
patent: WO95/29703 (1995-11-01), None
patent: WO95/30763 (1995-11-01), None
patent: PCT/US97/01609 (1997-04-01), None
patent: WO97/27319 (1997-07-01), None
patent: WO97/27480 (1997-07-01), None
patent: PCT/US98/15967 (1998-10-01), None
patent: WO99/06597 (1999-02-01), None
patent: PCT/US2003/013791 (2003-04-01), None
Blight et al. 2000, “Efficient Initiation of HCV RNA Replication in Cell Culture,”Science290:1972-1974.
Brown et al. 1994, “In Vitro Characterization of an Internal Ribosomal Entry Site (IRES) Present Within the 5′ Nontranslated Region of Hepatitis A Virus RNA: Comparison with the IRES of Encephalomyocarditis Virus,”Journal of Virology68(2): 1066-74.
Chou et al. 1995, “Frequency of UL97 Phosphotransferase Mutations Related to Ganciclovir Resistance in Clinical Cytomegalovirus Isolates,”The Journal of Infectious Diseases172:239-242.
Chung et al. 2001, “Hepatitis C Virus Replication is Directly Inhibited By IFN-α in a Full Length Binary Expression System,”Proc. Natl. Acad Sci USA, 98(17):9847-9852.
Enami et al. 1991, “High-Efficiency Formation of Influenza Virus Transfectants”Journal of Virology65(5):2711-13.
Enomoto et al. 1995, “Hepatitis C Virus Quasispecies Populations During Chronic Hepatitis C Infection”,Trends in Microbiology3(11):445-447.
Fuerst et al. 1986, “Eukaryotic Transient-Expression System Based on Recombinant Vaccinia Virus That Synthesizes Bacteriophage T7 RNA Polymerase,”Proc. Natl. Acad Sci USA, 83:8122-26.
Gerna et al. 1995, “Rapid Screening for Resistance to Ganciclovir and Foscarnet of Primary Isolates of Human Cytomegalovirus From Culture-Positive Blood Samples,”Journal of Microbiology, 33(3):738-741.
Glass et al. 1993, “Identification of the Hepatitis A Virus Internal Ribosome Entry Site: In Vivo and In Vitro Analysis of Bicistronic RNAs Containing the HAV 5′ Noncoding Region,”Virology, 193:842-852.
Hahm et al. 1996, “Generation of a Novel Poliovirus with a Requirement of Hepatitis C Virus Protease NS3 Activity,”Virology, 266:318-326.
Hirowatari et al. 1995, “A Novel Method for Analysis of Viral Proteinase Activity Encoded by Hepatitis C Virus in Cultured Cells,”Analytical Biochemistry, 225:113-120.
Houghton et al. 1996, “Hepatitis C Viruses” Fields Virology, 3rd Edition, Chapter 32: 1035-1058.
Jang et al. 1989, “Initiation of Protein Synthesis by Internal Entry of Ribosomes into the 5′ Nontranslated Region of Encephalomyocarditis Virus RNA In Vivo,”Journal of Virology, 63(4):1651-1660.
Kellam et al. 1992 “Fifth Mutation in Human Immunodeficiency Virus Type I Reverse Transcriptase Contributes to the Development of High-Level Resistance to Zidovudine”PNAS89:1934-1938.
Lawson et al. 1995, “Recombinant Vesicular Stomatitis Viruses From DNA,”Proc. Natl. Acad. Sci. USA, 63: 4477-4481.
Lu et al. 1996, “Poliovirus Chimeras Replicating Under the Translational Control of Genetic Elements of Hepatitis C Virus Reveal Unusual Properties of the Internal Ribosomal Entry Site of Hepatitis C Virus,”Proc Natl. Acad. Sci. USA, 93:1412-1417.
Mocarski, Edward S., 1996, “Cytomegaloviruses and Their Replication,” Fields Virology, 3rd Edition, Chapter 76, 2447-22492.
Morgenstern et al. 1990 “Advanced Mammalian Gene Transfer: High Titre Retroviral Vectors with Multiple Drug Selection Markers and a Complementary Helper-Free Packaging Cell Line,”Nucleic Acid Research18(12):3587-3596.
Pelletier et al. 1988, “Internal Initiation of Translation of Eukaryotic mRNA Directed by a Sequence Derived From Poliovirus RNA,”Nature, 334:320-325.
Rohll et al. 1994, “The 5′-Untranslated Regions of Picornavirus RNAs Contain Independent Functional Domains Essential for RNA Replication and Translation,”Journal of Virology, 68(7):4384-91.
Saltarelli et al. 1993 “The CAEV tat Gene Trans-Activates the Viral LTR and is Necessary for Efficient Viral Replication”,Virology197:35-44.
Schnell et al. 1994, “Infectious Rabies Viruses From Cloned cDNA,”The EMBO Journal, 13(18):4195-4203.
Steinkuhler et al. 1996, “Activity of Purified Hepatitis C Virus Protease NS3 on Peptide Substrates,”Journal of Virology, 70(10): 6694-6700.
Strair et al. 1993, “Recombinant Retroviral Systems for the Analysis of Drug Resistant HIV”,Nucleic Acids Research21(20):4836-4842.
Tsukiyama-Kohara et al. 1992, “Internal Ribosome Entry Site Within Hepatitis C Virus RNA,”Journal of Virology, 66(3): 1476-1483.
Wang et al. 1993, “Translation of Human Hepatitis C Virus RNA in Cultured Cells is Mediated by an Internal Ribosome-Binding Mechanism,”Journal of Virology, 67(6):3338-3344.
Danos, Olivier and Mulligan, Richard C. 1988, “Safe and Efficient Generation of Recombinant Retroviruses with Amphotropic and Ecotropic Host Ranges,”Proc. Natl. Acad Sci. USA, 85:6460-6464.
Fuerst, Thomas R., and Moss, Bernard 1989, “Structure and Stability of mRNA Synthesized by Vaccinia Virus-encoded Bacteriophage 17 RNA Polymerase in Mammalian Cells”J. Mol. Biol.206:333-348.
Lieber Andre et al. 1989, “High Level Gene Expression in Mammalian Cells by a Nuclear 17-Phage RNAPolymerase,”Nucleic Acids Research17(21):8485-8493.
Larder, Brendan A., et al. 1989, “HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy,”Science, 243:1731-1734.
Andreasson K.I., et al. 1989, “Production
Capon Daniel J.
Petropoulos Christos J.
Jones Day
Ketter James
Monogram Biosciences, Inc.
LandOfFree
Compositions and methods for determining anti-viral drug... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for determining anti-viral drug..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for determining anti-viral drug... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3862515